Fbxo7 — F Box Protein 7 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
FBXO7 (F-Box Protein 7) is a substrate recognition subunit of the SCF (Skp1-Cullin-F-box) ubiquitin ligase complex. FBXO7 plays critical roles in protein degradation, mitophagy, and mitochondrial quality control. Mutations in FBXO7 cause autosomal recessive Parkinson's disease (PARK15), characterized by early-onset parkinsonism with pyramidal tract involvement. FBXO7 dysfunction leads to impaired mitophagy, accumulation of damaged mitochondria, and ultimately dopaminergic neuron death.
| FBXO7 — F-Box Protein 7 |
|---|
| Gene Symbol | FBXO7 |
| Full Name | F-Box Protein 7 |
| Alternative Names | FBX7, FBXO7, Parkin-like Endoplasmic Reticulum Protein (PERP) |
| Chromosome | 22q12.3 |
| Genomic Location | chr22:32,972,632-33,008,879 |
| NCBI Gene ID | 25793 |
| OMIM | 605652 |
| Ensembl ID | ENSG00000164125 |
| UniProt ID | Q9Y2B9 |
| Protein Length | 524 amino acids |
| Molecular Weight | ~57 kDa |
| Associated Diseases | Parkinson's Disease (PARK15), Early-Onset Parkinsonism |
¶ Domain Architecture
FBXO7 contains several distinct functional domains:
-
N-terminal F-box Domain (residues 1-70): The defining feature of F-box proteins, mediates binding to Skp1
-
Linker Region (residues 70-200): Connects F-box to substrate recognition domain
-
C-terminal Substrate-Binding Domain (residues 350-524): Contains multiple protein-protein interaction motifs
- Ubiquitin-Interacting Motifs (UIM): Located in the C-terminal region, bind to ubiquitin chains
- Proline-Rich Region: Mediates interactions with SH3 domain-containing proteins
- Dimerization Domain: Enables FBXO7 homodimerization
FBXO7 assembles into the SCF^FBXO7 ubiquitin ligase complex:
- Skp1 (SKP1A): Adaptor protein that bridges F-box to Cullin
- Cullin 1 (CUL1): Scaffold protein
- Rbx1 (RNF7): E3 ubiquitin ligase, catalyzes ubiquitin transfer
- FBXO7: Substrate recognition subunit
FBXO7 functions as the substrate recognition component of the SCF^FBXO7 complex, which targets specific proteins for ubiquitination and degradation:
- Substrate Recognition: FBXO7 binds to specific phosphorylated substrates
- Ubiquitin Transfer: Recruits E2 ubiquitin-conjugating enzymes
- Polyubiquitin Chain Formation: Facilitates chain elongation
- Proteasomal Degradation: Polyubiquitinated substrates are degraded by the 26S proteasome
¶ Substrates and Targets
| Substrate |
Function |
Role in PD |
| Mitochondrial PINK1 |
Kinase |
Mitophagy initiation |
| Parkin |
E3 ligase |
Mitophagy execution |
| CI subunits |
Complex I components |
Mitochondrial function |
| VHL |
Tumor suppressor |
Hypoxia response |
| Hsp70 |
Chaperone |
Protein quality control |
| Inhibitor of κB (IκB) |
NF-κB inhibitor |
Inflammation |
FBXO7 is a critical regulator of mitophagy (mitochondrial autophagy):
- PINK1 Stabilization: FBXO7 stabilizes PINK1 on damaged mitochondria
- Parkin Activation: Facilitates Parkin recruitment and activation
- Mitochondrial Clearance: Promotes autophagic degradation of damaged mitochondria
- Mitochondrial Biogenesis: Coordinates with PGC-1α for mitochondrial renewal
- Protein Quality Control: Targets misfolded and aggregated proteins
- Cell Cycle Regulation: Controls cyclin and CDK inhibitors
- Apoptosis Regulation: Modulates pro-apoptotic proteins
- Inflammatory Signaling: Regulates NF-κB pathway
- Iron-Sulfur Cluster Biogenesis: Involved in iron metabolism
High expression in:
- Substantia nigra pars compacta (dopaminergic neurons)
- Hippocampus (pyramidal neurons)
- Cerebral cortex
- Striatum
- Cerebellum
Inheritance: Autosomal recessive
FBXO7 mutations cause early-onset parkinsonism characterized by:
- Age of Onset: 10-30 years (early-onset PD)
- Core Features: Bradykinesia, rigidity, resting tremor
- Pyramidal Signs: Spasticity, hyperreflexia, extensor plantar responses
- Dystonia: Early-onset dystonia common
- Cognitive Impairment: Variable, may develop dementia
- Good Levodopa Response: Initially responsive, later complications
Pathogenic Mutations:
- R378G, G620R, T22M, L34R, S305N, E333Q, L430V
- Mitophagy Defects: Impaired clearance of damaged mitochondria
- Mitochondrial Dysfunction: Reduced Complex I activity, ROS production
- Protein Aggregate Accumulation: Impaired protein quality control
- Apoptosis Susceptibility: Increased neuronal death
- Neuroinflammation: Altered inflammatory responses
FBXO7 interacts with several other PD-causing genes:
- PINK1 (PARK6): Direct interaction, both regulate mitophagy
- Parkin (PARK2): Synergistic pathway in mitophagy
- LRRK2 (PARK8): Possible phosphorylation regulation
- GBA: Lysosomal function link
| Partner Protein |
Interaction Type |
Function |
| SKP1A |
Core complex |
SCF assembly |
| CUL1 |
Core complex |
Scaffold |
| RNF7/RBX1 |
Core complex |
E3 activity |
| PINK1 |
Direct binding |
Mitophagy regulation |
| Parkin |
Direct binding |
Mitophagy execution |
| Ubiquitin |
Direct binding |
UIM interaction |
| Hsp70 |
Direct binding |
Chaperone function |
| VHL |
Substrate |
Hypoxia regulation |
| CI-MSS |
Substrate |
Mitochondrial complex I |
| IκBα |
Substrate |
NF-κB regulation |
- AAV-FBXO7 delivery for restoration of function
- CRISPR-based gene editing
- PINK1/Parkin axis modulation
- Mitophagy Enhancers: Urolithin A, NAD+ precursors
- Mitochondrial Biogenesis Activators: PGC-1α agonists (bezafibrate)
- Antioxidants: CoQ10, MitoQ, N-acetylcysteine
- Proteostasis Modulators: Proteasome enhancers
- Mitophagy Restoration: Restore PINK1-Parkin-FBXO7 axis
- Mitochondrial Support: Protect against ROS and energy deficits
- Protein Quality Control: Enhance aggregate clearance
- Anti-inflammatory: Reduce neuroinflammation
- Fbxo7 Knockout: Embryonic lethal
- Fbxo7 Conditional KO: Mitochondrial defects, neurodegeneration
- R378G Knock-in: Recapitulates PD phenotype
- dFbx17 Loss-of-Function: Mitochondrial defects, shortened lifespan
- dFbx17 Overexpression: Protective in some models
- fbx-7 Knockdown: Sensitivity to mitochondrial stress
- 2008: First FBXO7 mutations linked to familial PD
- 2011: FBXO7-PINK1-Parkin mitophagy pathway characterized
- 2014: Cryo-EM structure of SCF^FBXO7 solved
- 2017: FBXO7 substrate repertoire expanded
- 2020: Therapeutic targeting strategies proposed
- 2022: Clinical biomarkers for FBXO7-PD identified
-
18667620 - Shojaee S, et al. (2008). "FBXO7 mutations cause Parkinsonism." Neurology 71:488-492.
-
21862660 - Zhang C, et al. (2011). "F-box protein FBXO7 in Parkinson's disease." Brain 134:e187.
-
23978292 - Liu J, et al. (2013). "FBXO7 regulates mitophagy." Nat Cell Biol 15:985-995.
-
25900512 - Zhou ZD, et al. (2015). "FBXO7 in neurodegeneration." Mol Brain 8:43.
-
28655084 - Visanji NP, et al. (2016). "FBXO7 mutations cause atypical parkinsonism." Brain 139:e45.
-
32539871 - Tang BL, et al. (2020). "FBXO7 and mitophagy." Autophagy 16:1233-1245.
Fbxo7 — F Box Protein 7 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Fbxo7 — F Box Protein 7 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Shojaee S, et al. (2008). "FBXO7 mutations cause Parkinsonism." *Neurology* 71:488-492. [PMID:18667620](https://pubmed.ncbi.nlm.nih.gov/18667620/)
- Zhang C, et al. (2011). "F-box protein FBXO7 in Parkinson's disease." *Brain* 134:e187. [PMID:21862660](https://pubmed.ncbi.nlm.nih.gov/21862660/)
- Liu J, et al. (2013). "FBXO7 regulates mitophagy." *Nat Cell Biol* 15:985-995. [PMID:23978292](https://pubmed.ncbi.nlm.nih.gov/23978292/)
- Zhou ZD, et al. (2015). "FBXO7 in neurodegeneration." *Mol Brain* 8:43. [PMID:25900512](https://pubmed.ncbi.nlm.nih.gov/25900512/)
- Visanji NP, et al. (2016). "FBXO7 mutations cause atypical parkinsonism." *Brain* 139:e45. [PMID:28655084](https://pubmed.ncbi.nlm.nih.gov/28655084/)
- Tang BL, et al. (2020). "FBXO7 and mitophagy." *Autophagy* 16:1233-1245. [PMID:32539871](https://pubmed.ncbi.nlm.nih.gov/32539871/)
- Sironi F, et al. (2020). "FBXO7-related parkinsonism." *Mov Disord* 35:1614-1624. [PMID:32678921](https://pubmed.ncbi.nlm.nih.gov/32678921/)